Compare NSP & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | DMRA |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | NSP | DMRA |
|---|---|---|
| Price | $48.35 | $28.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $47.67 | $43.00 |
| AVG Volume (30 Days) | 591.0K | ★ 841.0K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $6,812,000,000.00 | N/A |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $54.52 | ★ N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $18.57 | $16.50 |
| 52 Week High | $61.65 | $34.89 |
| Indicator | NSP | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 53.60 |
| Support Level | $32.75 | $22.71 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.38 | 2.72 |
| MACD | -0.17 | -0.19 |
| Stochastic Oscillator | 66.08 | 35.35 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.